SCI frontier: YeaSense's breakthrough in the field of antibiotic replacement
Recently, the scientific papers on YeaSense have been included in SCI, the influencing factor is 3.289. In this paper YeaSense is called "yeast glycoprotein". This means that in the field of alternative antibiotics application, yeast products have made breakthrough research progress.
This paper was published by Angel Yeast Co., Ltd. and the Chinese Academy of Sciences. The changes of growth performance, intestinal mucosal morphology, immune response and colonic microflora of weaned piglets after YeaSense replaced AGPs in diets were studied. The results show that YeaSense is an effective alternative to antibiotics.
Brief introduction of research results
240 weaned piglets were fed with 800 g/t YeaSense instead of 25% quinolone 200 g/t + 4% enramycin 800 g/t. The results are as follows:
• Improve the growth performance of weaned piglets:
Increase end-stage body weight (0.05 < P < 0.1), increase daily gain (P < 0.05), and decrease feed-meat ratio (P < 0.05).
• Improve intestinal health
1. Reduce intestinal permeability
Serum DAO examination can reveal the extent of intestinal mucosal injury. When intestinal mucosal epithelial cells and barrier function were damaged, DAO release increased, and DAO entered extracellular space, lymphatic vessels and blood flow, thus increasing serum DAO level. Therefore, DAO activity is a marker of damage and repair of intestinal barrier structure, reflecting the maturity of intestinal epithelial cells and the permeability of intestinal mucosa. Piglets in the antibiotic group contained more DAO, indicating that antibiotics had some damage to the intestinal mucosa of piglets. YeaSense can reduce the serum DAO (diamine oxidase) content (P < 0.01), thus reducing intestinal permeability.
2. Promote intestinal mucosal development and ensure intestinal structural integrity
3. Increase the relative richness of lactic acid bacteria
The results of colonic microflora showed that the addition of YeaSense increased the relative abundance of lactic acid bacteria (P < 0.05).
• Relaxation of inflammation
Interestingly, YeaSense can relieve inflammation. YeaSense decreased the expression of interleukin-12 (IL-12) and increased the expression of Hsp-70 (heat shock protein-70) in duodenal mucosa (P < 0.05). In jejunal mucosa, YeaSense decreased the expression of m-RNA in Hsp-70 (P < 0.05), decreased IFN-gamma (P < 0.05), and increased the expression of m-RNA in Hsp-90 (P < 0.05). YeaSense increased the expression of m-RNA in Hsp-70 in ileal mucosa (P < 0.05). It shows that YeaSense not only reduces systemic inflammation, but also local inflammation.
• Reduce satiety
The results of colon metabolites test showed that YeaSense could reduce acetate content (P < 0.05). Acetate is one of the short-chain fatty acids (SCFAs) produced by microbial fermentation, and is the most abundant SCFAs in the peripheral circulation. Acetate passes through the blood-brain barrier through the central homeostasis mechanism and reduces appetite. YeaSense can reduce intestinal acetate content, thereby reducing satiety and increasing food intake.
Title and abstract of the original paper:
Title: "Effects of dietary supplementation with yeast glycoprotein on growth performance, intestinal mucosal morphology, immune response and colonic microbiota in weaned piglets".
Abstract: Antibiotics are commonly provided to weaned piglets, however, this practice has become controversial due to increased occurrences of microbial resistance, and alternatives are needed. This study aimed to investigate the effects of dietary supplementation with yeast glycoprotein (YG) or antibiotics on growth performance, intestinal mucosal morphology, immune response and colonic microbiome in weaned piglets. A total of 240 weaned piglets (d 23 ± 2) from 16 pens (15 piglets/pen) were randomly assigned into an antibiotics group (25% Quinocetone 200 mg/kg and 4% Enduracidin 800 mg/kg of the basal diet), or a YG group (800 mg/kg YG of the diet), respectively. One piglet per pen was chosen to collect plasma, intestinal tissue and colonic digesta samples after 14 days feedings. The results indicate that piglets fed diets containing YG tended to increase final body weight (0.05<P<0.1), increased average daily gain (P<0.05) and decreased F/G (P<0.05) when compared with antibiotics group. Moreover, intestinal permeability showed that YG led to lower serum content of DAO (P<0.01). Histological evaluations showed that YG contributed to improving the intestinal development via increasing villous height (P<0.05) and the villous height to crypt depth ratio (P<0.01), decreasing crypt depth (P<0.01) and villous width (P<0.05) in the ileum. Intestinal integrity also showed that YG conduced to improving the intestinal development via upregulating the m-RNA expression of occludin (P<0.05) in the duodenal and jejunal mucosa. Interestingly, YG supplement downregulated the m-RNA expression of IL-12 (P<0.05), upregulated the m-RNA expression of Hsp-70 (P<0.05) in the duodenal mucosa, downregulated the m-RNA expression of Hsp-70 (P<0.05), IFN-γ (P<0.05), upregulated the m-RNA expression of Hsp-90 (P<0.05) in the jejunal mucosa, and upregulated the m-RNA expression of Hsp-70 (P<0.05) in the ileal mucosa. On the other hand, colonic microbiome results showed that YG supplement increased the relative abundance of Lactobacillus (P<0.05). Colonic metabolites results showed that YG supplement decreased the content of acetate (P<0.05). Taken together, it is speculated that YG would be a potent alternative to prophylactic antibiotics in improving the gut health in weaned piglets.
For more of the article, please click here.
Article made possible through the contribution of Angel Yeast Co., Ltd.